AU2021327085A1 - Peptides for use in the treatment or prevention of myocardial damage - Google Patents

Peptides for use in the treatment or prevention of myocardial damage Download PDF

Info

Publication number
AU2021327085A1
AU2021327085A1 AU2021327085A AU2021327085A AU2021327085A1 AU 2021327085 A1 AU2021327085 A1 AU 2021327085A1 AU 2021327085 A AU2021327085 A AU 2021327085A AU 2021327085 A AU2021327085 A AU 2021327085A AU 2021327085 A1 AU2021327085 A1 AU 2021327085A1
Authority
AU
Australia
Prior art keywords
peptide
subject
tat
aid
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021327085A
Other languages
English (en)
Inventor
Livia HOOL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Western Australia
Original Assignee
University of Western Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020902986A external-priority patent/AU2020902986A0/en
Application filed by University of Western Australia filed Critical University of Western Australia
Publication of AU2021327085A1 publication Critical patent/AU2021327085A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
AU2021327085A 2020-08-21 2021-08-20 Peptides for use in the treatment or prevention of myocardial damage Pending AU2021327085A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020902986A AU2020902986A0 (en) 2020-08-21 Peptides for Use in the Treatment or Prevention of Myocardial Damage
AU2020902986 2020-08-21
PCT/AU2021/050928 WO2022036411A1 (en) 2020-08-21 2021-08-20 Peptides for use in the treatment or prevention of myocardial damage

Publications (1)

Publication Number Publication Date
AU2021327085A1 true AU2021327085A1 (en) 2023-03-02

Family

ID=80322294

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021327085A Pending AU2021327085A1 (en) 2020-08-21 2021-08-20 Peptides for use in the treatment or prevention of myocardial damage

Country Status (8)

Country Link
US (1) US20240158447A1 (https=)
EP (1) EP4200314A4 (https=)
JP (1) JP7776492B2 (https=)
KR (1) KR20230054440A (https=)
CN (1) CN116615438A (https=)
AU (1) AU2021327085A1 (https=)
CA (1) CA3189838A1 (https=)
WO (1) WO2022036411A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491523B2 (en) * 2004-05-11 2009-02-17 Hirsch Joel A Voltage-dependent calcium channel beta subunit functional core
EP2173372B1 (en) * 2007-06-18 2014-11-19 Agency for Science, Technology and Research Novel peptides and protein and uses thereof
WO2013113060A1 (en) * 2012-01-31 2013-08-08 The University Of Western Australia Peptide
US11474098B2 (en) * 2017-12-22 2022-10-18 The Trustees Of Columbia University In The City Of New York Drug target for preventing pathologic calcium overload in cardiomyocytes and methods of screening for same

Also Published As

Publication number Publication date
KR20230054440A (ko) 2023-04-24
WO2022036411A9 (en) 2025-10-02
JP2023537934A (ja) 2023-09-06
EP4200314A4 (en) 2025-01-01
CA3189838A1 (en) 2022-02-24
JP7776492B2 (ja) 2025-11-26
CN116615438A (zh) 2023-08-18
EP4200314A1 (en) 2023-06-28
US20240158447A1 (en) 2024-05-16
WO2022036411A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
KR102268883B1 (ko) 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
JP6046493B2 (ja) プロミニン−１の血管新生促進フラグメントおよびその使用
JP2009531036A (ja) Ｖｅｇｆ受容体融合タンパク質およびそれらの使用
JP2011529505A (ja) プロミニン−１ペプチド断片およびその使用
JP2017197581A (ja) バイグリカン変異体および関連する治療薬および使用方法
RU2685869C1 (ru) Варианты дизинтегрина и их фармацевтическое применение
US8409826B2 (en) TAT-utrophin as a protein therapy for dystrophinopathies
JP2016535080A (ja) 療法における使用のためのインスリン様成長因子模倣物
JP4808623B2 (ja) 血管形成を減少させるためのクラスｉｉｉのｓｌｒｐのアゴニスト
AU2021327085A1 (en) Peptides for use in the treatment or prevention of myocardial damage
AU2016203988B2 (en) Protein to promote blood vessel growth and uses thereof
AU2008265840B2 (en) A method of treating abnormal angiogenesis via the BAI family of proteins and their protein fragments
US20140303093A1 (en) Micro-utrophin polypeptides and methods
JP2025534734A (ja) 心筋細胞を保存及び保護し、心損傷後の心筋線維化を軽減する方法
WO2013113060A1 (en) Peptide
US20220133849A1 (en) Compositions and methods for the treatment of smooth muscle dysfunction
CN120676931A (zh) Engrailed蛋白的稳定水性组合物
JP2011529452A (ja) 抗血管新生薬としての可溶性ｉｇｆ受容体
Belanto A Biochemical and Molecular Analysis of Functional Differences between Dystrophin and Utrophin
HK40000030B (en) Compositions and methods for treating retinopathy
HK40000030A (en) Compositions and methods for treating retinopathy
CN108697772A (zh) 用于治疗视网膜病的组合物和方法